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Alfred E. Chang, MD 
Background: Adoptive immunotherapy of malignancy involves the passive 
transfer of antitumor-reactive ceils into a host in order to mediate tumor re- 
gression. Based on animal models, the transfer of immune lymphoid cells can 
eradicate widely disseminated tumors and establish long-term systemic immu- 
nity. Critical for successful adoptive immunotherapy is the ability to isolate 
large numbers of immune cells. For clinical therapy, it will require the devel- 
opment of in vitro methods to promote the sensitization and propagation of 
tumor-reactive cells. However, this is a formidable task since human cancers 
are postulated to be poorly immunogenic because of their spontaneous origins. 
Results: Human lymphoid cells for ex vivo activation and subsequent adop- 
tive transfer have been derived from different sources, including peripheral 
blood, tumor, and lymph nodes. Peripheral blood tymphocytes can be incu- 
bated with interleukin 2 to generate lymphokine-activated killer (LAK) cells, 
which nonspecifically lyse autologous and allogeneic tumor cells in vitro. LAK 
cell therapy represented the earliest attempt to treat advanced human cancers, 
with encouraging results documented in patients with renal cell cancer and 
melanoma. From that experience, the use of more immunologically specific 
cellular agents with potentially greater therapeutic efficacy has been investi- 
gated. One approach uses tumor-infiltrating lymphocytes, which have been 
characterized experimentally to be more specific in tumor reactivity compared 
with LAK cells. Other techniques have involved the use of lymphoid cells 
derived from lymph nodes draining tumors or primed by tumor vaccines. In 
vitro activation of these cells with tumor antigen or anti-CD3 monoclonal an- 
tibody results in the generation of T cells that mediate the rejection of poorly 
immunogenic tumors in animal studies. These alternate methods are currently 
being evaluated in clinical studies. 
Conclusions: Experimentally, cellular therapy is a potent method to eradicate 
progressive tumors. Initial clinical studies have demonstrated that this form of 
therapy is technically feasible and can result in meaningful antitumor re- 
sponses. Advances in this area will require improved methods to sensitize, 
isolate, and expand tumor-reactive T cells for adoptive transfer. 
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Ever  since experimental  tumors  were  d iscovered  
to express  unique antigens subject to tumor-specif ic 
transplantation rejection, immunotherapeut ic  meth- 
ods to treat  cancer  have been intensely studied. Un- 
like the success seen in clinical t ransplantat ion,  
s temming from the possibility of  suppressing the 
immune system, a t tempts  at enhancing immuno-  
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logic function to specifically reject progressively 
growing human tumors have been less straightfor- 
ward. Immunotherapy of cancer can be broadly 
classified into two major categories: active and pas- 
sive immunotherapy. Active immunotherapeutic 
approaches rely upon the stimulation of endoge- 
nous host immune elements to react against tumor 
antigens. By contrast, passive immunotherapy in- 
volves the administration of agents that have been 
characterized to have antitumor reactivity, in order 
to mediate a therapeutic effect in the host. These 
approaches have been established initially in animal 
models and have helped define basic principles of 
the host's immune response against progressive tu- 
mor. 
One of the earliest attempts in cancer immuno- 
therapy was active immunotherapy with nonspe- 
cific immune stimulants. This approach was based 
on the hypothesis that nonspecific immune stimula- 
tion of the host would result in an increased reac- 
tivity to putative tumor antigens on growing can- 
cers. Bacterial and pharmacological immune stimu- 
lants, including Bacillus Calmette-Gudrin (BCG), 
Corynebacterium parvum (C. parvum), Nocardia 
rubra, and levamisole, were employed in the 1970s 
to induce systemic immunity. However, these clin- 
ical trials failed to show consistent therapeutic ben- 
efits in cancer patients treated with these nonspe- 
cific immune stimulants (1). More recently, the 
availability of cytokines has afforded the clinician 
the ability to treat metastatic disease by modulation 
of the host's immune response. The cytokine that 
has been studied the most is interleukin 2 (IL-2); it 
has been documented to have limited therapeutic 
efficacy against melanoma and renal cell carcino- 
mas. From several studies, the response rates with 
IL-2 therapy for these cancers are between I0 and 
20% (2-5). 
Another form of active immunotherapy that has 
been investigated for many years is the use of tumor 
vaccines. This method has also been referred to as 
active specific immunotherapy. A potential obsta- 
cle to this approach is the weak immunogenicity of 
human cancers by virtue of their spontaneous ori- 
gins. Moreover, the host may be partly immunosup- 
pressed from the presence of progressively growing 
tumor. To help overcome these obstacles, irradi- 
ated tumor cells were often mixed with an immune 
adjuvant, such as BCG, or otherwise manipulated 
to become more effective at stimulating a host re- 
sponse. More recently, genetic modification of tu- 
mor cells has been reported to increase tumor im- 
munogenicity and may serve to produce more po- 
tent tumor vaccines. In animal models, transfection 
of tumors with various cytokine genes, allogeneic 
major histocompatibility complex antigens or im- 
mune costimulatory molecules have been shown to 
increase the host immune response against unmod- 
ified, parental tumor cells (6--13). The efficacy of 
gene-modified tumor cells in clinical active specific 
immunotherapy is currently being examined in clin- 
ical trials. 
The other major category of immunotherapies is 
passive immunotherapy. The two most common el- 
ements of passive immunotherapy are tumor- 
reactive antibodies and cellular reagents. The use of 
specific antibodies for cancer therapy is also re- 
ferred to as "passive immunization"; it has been 
explored for many years with somewhat disappoint- 
ing results (14-16). However, efforts to produce bi- 
functional conjugates of toxins or radiochemicals 
coupled to antibodies specific for tumor cells have 
been encouraging (17,18). Evidence suggesting the 
existence of common tumor antigens lends impetus 
to this type of approach, but clinical utility still must 
be confirmed (19,20). This review will focus on the 
different approaches of passive cellular therapy that 
have been established in animal studies and their 
application in clinical trials. 
ADOPTIVE IMMUNOTHERAPY 
Immune rejection of tumors has been demon- 
strated to be T cell mediated, with antibodies play- 
ing an insignificant role in this phenomenon. His- 
torically, the passive transfer of T cells, but not 
serum, from an immunized animal to a naive host 
conferred protective immunity to subsequent tumor 
challenges. While such immune T cells clearly me- 
diate a protective antitumor effect, they also show 
therapeutic utility in the treatment of established 
tumors (21,22). This form of therapy has also been 
termed "adopt ive  immunotherapy" .  Important 
principles of adoptive immunotherapy established 
from animal studies are: 
1. Syngeneic (or autologous) immune ceils are 
more efficacious than allogeneic and xenogeneic 
cells. 
2. The therapeutic efficacy of immune cells is de- 
pendent on the number of cells transferred. 
3. Tumor-induced suppression of the host immune 
response to tumor has been demonstrated. 
4. Tumors vary in degree of immunogenicity. 
5. Lymphoid cells derived from tumor-immune an- 
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imals can be cultured in vitro and still retain anti- 
tumor activity when passively transferred in vivo. 
6. Concomitant administration of IL-2 can enhance 
the in vivo therapeutic activity of cultured im- 
mune cells. 
Using inbred strains of mice, it was noted that 
successful adoptive immunotherapy of established 
tumor required the transfer of large numbers of im- 
mune lymphocytes derived from syngeneic donor 
mice that were hyperimmunized against the same 
tumor. Obviously, this approach cannot be directly 
applied to the treatment of human cancers since 
genetically identical individuals are not available as 
a source of immune lymphocytes. Therefore, one 
critical problem in the development of clinical adop- 
tive immunotherapy has been finding a source of 
immune cells that can be obtained from the cancer 
patient. Unfortunately, cancer patients probably 
represent a preselected population who lack the 
ability to adequately respond to their own tumors. 
Moreover, animal studies have shown the existence 
of tumor-induced immunosuppression that may in- 
terfere with the sensitization of lymphoid cells or 
their ability to mediate antitumor effects (23-25). 
Therefore, it became apparent that the generation 
of large numbers of functional T cells with specific 
antitumor reactivity was going to be dependent 
upon designing in vitro methods to further sensitize 
and expand lymphoid cells from the tumor-bearing 
host. In this regard, a succession of lymphocyte 
activation strategies have been examined in an at- 
tempt to generate therapeutic cellular agents. In- 
cluded in this list are lymphokine-activated killer 
(LAK) cells, tumor-infiltrating lymphocytes (TILs), 
in vitro sensitized lymphocytes, and anti~CD3/IL-2 
activated lymphocytes. 
Lymphokine-activated killer cells 
The incubation of lymphoid cells in high concen- 
trations of IL-2 results in the generation of LAK 
cells, a phenomenon described by Grimm et al. (26). 
LAK cells are characterized as non-T, non-B lym- 
phoid cells that mediate the nonspecific in vitro cy- 
tolysis of autologous as well as allogeneic tumor 
cells. This phenomenon is distinct from that char- 
acteristic of conventional cytotoxic T lymphocytes 
(CTLs), where sensitized T cells mediate immuno- 
logically specific tumor cytotysis in vitro. The spe- 
cific cytotoxicity manifested by CTLs requires that 
they share the same class I major histocompatibility 
(MHC) antigens as the tumor to which they are sen- 
sitized, whereas the nonspecific tumor cytotoxicity 
mediated by LAK cells does not have such MHC 
restriction. Nevertheless, LAK cells were found to 
have in vivo therapeutic efficacy in the treatment of 
micrometastatic tumor (27,28). Mice with estab- 
lished 3-day pulmonary metastases had significant 
tumor regression when treated with LAK cells ad- 
ministered in conjunction with IL-2 (Fig. 1). These 
investigations have shown that the in vivo antitu- 
mot effects of LAK cells were nonspecific and 
highly dependent on the concomitant administra- 
tion of IL-2. 
Based on these exper imental  observat ions,  
Rosenberg and co-workers at the National Cancer 
Institute (NCI) conducted the first human trial of 
adoptive immunotherapy with autologous LAK 
cells and IL-2, which was reported in 1985 (29). In 
that study, 25 patients with advanced cancer (i.e., 
melanoma and renal cell, colon, and lung cancer) 
were treated with ~<1.8 x I0 ~1 LAK cells generated 
from peripheral blood lymphocytes (PBLs) ob- 
tained through several leukaphereses. They were 
also given bolus infusions of IL-2 at maximum tol- 
erated doses. Eleven of the patients experienced 
measurable tumor regressions: one complete and 10 
partial. This study heralded the feasibility of acti- 
vating large numbers of lymphocytes ex vivo for 
adoptive immunotherapy of human cancer. Be- 
cause this early experience indicated that patients 
with melanoma and renal cell cancer were most re- 
sponsive, subsequent studies mainly focused on pa- 
FIG. t. Adoptive immunotherapy of 3-day MCA 105 pulmonary 
micrometastases with LAK cells and IL-2. Whole lungs were 
harvested 14 days after i.v. tumor inoculation and insuffiated 
with India ink via the trachea to allow enumeration of the white 
lung tumors. Lungs on the left are from control mice without 
treatment, and lungs on the right are from animals treated with 
LAK cells and nontherapeutic doses of IL-2 (28). 
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tients with these tumor histologies. Table 1 summa- 
rizes the results of using LAK cells plus IL-2 in the 
treatment of advanced melanoma and renal cell can- 
cer at several institutions (30--40). In 190 patients 
with melanoma, there was a response rate (com- 
plete and partial) of 16%. Among 198 patients with 
renal cell cancer, the response rate was 22%. In 
these two populations of patients, sites of tumor 
regression included liver, lung, bone, skin subcuta- 
neous tissue, and lymph nodes. It is noteworthy 
that if tumor regressed at one site in a patient, it 
usually was associated with tumor regression at all 
sites of disease (30). In addition, a large proportion 
of patients who experienced complete responses 
maintained these responses over a long period of 
time. 
Analyses of factors associated with tumor re- 
sponses from LAK and IL-2 therapy have turned up 
no consistent findings. The number of LAK cells 
infused, the in vitro lyric activity of the LAK cells, 
and the total amount of IL-2 administered were not 
predictive of achieving a tumor response. The tox- 
icities associated with the therapy were mainly due 
to the effects of IL-2. Multiple organ toxicity asso- 
ciated with IL-2 infusion can be attributed mostly to 
induction of a capillary leak syndrome, marked 
lymphocytic infiltration within visceral organs, and 
elaboration of other cytokines in response to IL-2 
T A B L E  1. Eff icacy  o f  L A K  cells and 1L-2 in 
(41). The severity of these toxicities were clearly 
associated with the cumulative amount of IL-2 ad- 
ministered. Fortunately,  these toxicities were 
quickly reversible once IL-2 therapy was discontin- 
ued. 
Since high-dose IL-2 alone was shown to have 
antitumor efficacy in patients with advanced mela- 
noma and renal cell cancer, it was important to de- 
termine whether the addition of LAK cells offered 
any improved therapeutic benefit. In a multiinstitu- 
tional trial, 167 patients with advanced melanoma 
and renal cell cancer were randomized to receive 
LAK cells plus IL-2 or IL-2 only (42). No signifi- 
cant difference between the treatment arms was ob- 
served. In melanoma patients, the response rates 
for LAK/IL-2 and IL-2 were 12% and 16%, respec- 
tively. In renal cell cancer patients, the response 
rates for LAK/IL-2 and IL-2 were 13% and 8%, 
respectively. In a similar prospective, randomized 
trial conducted by Rosenberg et al. at the NCI, the 
response rates in patients with melanoma and renal 
cell cancer were not statistically different for L A K /  
IL-2 versus IL-2 therapy (43). However, there was 
a trend toward more complete responses in patients 
treated with LAK/IL-2 versus IL-2 only, and there 
was a trend toward improved survival in patients 
with melanoma randomized to receive LAK/IL-2 
compared with IL-2 alone. These LAK cell trials 
the therapy of renal cell carcinoma and melanoma 
No. of  No. of  
Author  patients L A K  cells a 
IL-2 Tumor responses  
infusion CR PR CR + PR 
Melanoma 
Rosenberg (30) 34 7.9 x 101° 
West et al. (31) I0 6 .89 .1  x 101° 
Schoof  et al. (32) 9 4.3 x 10 I° 
Thompson et al. (33) 8 3.4--4.3 x 10 l° 
Paciucci et al. (34) 5 3.4 x 10 l° 
Dutcher et al. (35) 36 8.9 x 101° 
Bar et al. (36) 55 8.3 x 101° 
Dutcher  et al. (37) 33 1.6 x 1011 
Total 190 
Renal cell cancer 
Rosenberg (30) 54 7.9 x 101° 
West  et al. (31) 6 6.8-9.1 x 101° 
Schoof  et al. (32) 10 4.3 x 101° 
Thompson et al. (33) 8 3.4--4.3 x 10 l° 
Paciucci et al. (34) 32 4 .96 .1  x t0 ~° 
Wang et al. (38) b 9 3.4 x 10 TM 
Fisher et al. (39) 32 7.0 x 10 TM 
Parkinson et al. (40) 47 9.2 × 1011 
Total 198 
Bolus 3 3 6 
CI 0 5 5 
Bolus 1 4 5 
Bolus/CI 0 0 0 
CI 0 1 1 
Bolus 1 5 6 
CI 1 6 7 
CI 0 1 
6 25 31 (16%) 
Bolus 7 10 17 
CI 0 3 3 
Bolus 0 5 5 
Bolus/CI 1 0 1 
CI 2 5 7 
CI 0 1 1 
Bolus 2 3 5 
CI 2 2 2 
t4 29 43 (22%) 
CI, continuous infusion; CR, complete response (regression 
evaluable tumor). 
Represents  mean or median number of  cells. 
b Modified L A K  generated by periodate and IL-2. 
of  all evaluable tumor); PR, partial response (/>50% regression of  all 
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stimulated efforts to find more potent cellular 
agents. From animal studies, it was evident that the 
therapeutic efficacy of passive cellular therapy was 
enhanced as the cellular specificity toward the in- 
dividual neoplasm increased. 
Tumor-infiltrating lymphocytes 
One such population of tumor-specific T cells are 
TILs. TILs are generated by the culture of dissoci- 
ated cells from solid tumors in high concentrations 
of IL-2. Rosenberg et al. found that adoptive immu- 
notherapy with TILs significantly prolonged sur- 
vival in mice with advanced pulmonary metastases 
that were refractory to LAK cells (44). Optimal 
treatment included cyclophosphamide, followed by 
the administration of TILs and IL-2 (Fig. 2). The 
role of cyclophosphamide in this model is not 
clearly understood. It may have acted to lower tu- 
mor-induced immunosuppression or it may have 
served as a cytoreductive agent. In contrast to LAK 
cells, TILs have been shown to have relatively 
more specific immunoreactivity against the tumor 
of origin in in vitro cytotoxicity assays. This tumor 
specificity was associated with a 50- to 100-fold in- 
creased efficacy in the reduction of lung metastases 
when compared with LAK cells (45). 
In patients with metastatic melanoma, adoptive 
immunotherapy with autologous TILs and IL-2 
with or without cyclophosphamide resulted in a 
38% combined partial and complete response rate at 
the NCI (46). Compared with the LAK/IL-2 trials in 
melanoma, this rate suggested that TIL therapy 
may be more efficacious in the treatment of mela- 
noma. However, problems with the consistent cul- 
ture and expansion of lymphocytes from resected 
tumor along with the labor-intensive laboratory pro- 
cedures necessary to generate large numbers of 
TILs for therapy have limited widespread clinical 
application of this technique. There has been very 
little clinical experience outside the NCI with the 
use of large numbers (> 1011) of TILs for therapy. In 
renal cell cancer, Bukowski et al. reported no re- 
sponses in 18 patients treated with large numbers of 
TILs and escalating doses of IL-2 (47). This finding 
may reflect that certain tumor histologies are not 
amenable to the generation of therapeutically effec- 
tive TILs. It is evident that the optimal conditions 
for TIL culture and expansion as well as its clinical 
applications need to be further defined. 
In vitro sensitized cells 
We have developed a technique of promoting the 
stimulation and growth of tumor-specific lympho- 
cytes called in vitro sensitization (IVS) (48,49). This 
technique involves the culture of lymphocytes with 
irradiated tumor-stimulator cells in the presence of 
low concentrations of IL-2. In animal studies, we 
examined the antitumor reactivity of lymphoid cells 
from normal and tumor-bearing mice that had been 
cultured by the IVS technique. We found that 
freshly harvested tumor-draining lymph node 
(TDLN) cells had no therapeutic effect in adoptive 
immunotherapy experiments; however, after IVS 
culture, this lymphocyte population was found to be 
very effective at mediating the regression of 3-day 
pulmonary metastases (Table 2). Since in vitro sen- 
sitized cells derived from the spleens of normal 
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FIG. 2. Adoptive immunotherapy of ad- 
vanced MC-38 pulmonary metastases with TIL. 
Treatment of mice with advanced pulmonary 
metastases from the immunogenic MC-38 colon 
adenocarcinoma. This figure summarizes two 
experiments in which treatment was begun 12 
and 14 days, respectively, after i.v.injection of 
tumor cells. Mice received cyclophosphamide 
(Cy) at 100 mg/kg i.v. 6 h before TIL (2-2.4 x 
107 cells Lv.) and IL-2 (20,000 U i.p. every 8 h 
for 5 days) were given (44), 
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TABLE 2. Adoptive immunotherapy of MCA 105 
pulmonary metastases with fresh noncultured or in vitro 
sensitized cells from mice bearing progressive MCA 
105 tumors 
Mean no. of pulmonary metastases (SEM) ~ 
Source of Fresh In vitro sensitized 
lymphoid ceUs a lymphoid cells lymphoid cells 
- -  136 (33) 171 (51) 
Normal spleens 127 (37) 91 (46) 
Immune spleens 2 (1) c 1 (1) c 
Tumor-draining 
lymph nodes 86 (26) 2 (1) c 
Modified from Shu et al. (48). 
Lymphoid cells from spleens or lymph nodes of normal or 
MCA 105 immune mice or mice bearing 14-day s.c. MCA 105 
tumor. 
b Fresh lymphoid ceils (1.5 x 108 spleen cells or 6 x 10 7 lymph 
node cells) or in vitro sensitized lymphoid cells (2 x 107) were 
given i.v. to mice with established 3-day MCA 105 pulmonary 
metastases. Animals receiving in vitro sensitized cells also were 
given 7,500 U IL-2 i.p. twice daily for 3 days after cell transfer. 
Pulmonary metastases were counted on day 14. 
c p < 0.05 compared with groups of mice not treated with 
cells. 
tion of tumor-sensitized cells in TDLN cells must 
have occurred during progressive tumor growth. 
Although lacking functional antitumor reactivity 
when initially removed, these "preeffector" cells 
differentiated during IVS culture to become thera- 
peutically active effector cells. Further studies 
showed that in vitro sensitized cells derived from 
TDLN cells were effective in the treatment of ad- 
vanced metastatic disease in the absence of cyclo- 
phosphamide (Fig. 3) (50). 
As alluded to previously, the immunogenicity of a 
tumor may be a significant factor in its ability to 
generate antitumor reactive T cells. For example, 
TILs derived from poorly immunogenic animal tu- 
mors have been therapeutically ineffective in adop- 
tive immunotherapy experiments (45). Using these 
same tumors, we also observed that TDLN cells 
cultured in IVS did not result in the generation of 
functionally active effector cells. These observa- 
tions underscore the problem with the immunother- 
apy of poorly immunogenic tumors, which more 
closely resemble human cancers. Nevertheless, we 
were able to develop an alternative approach to 
elicit preeffector cells in the host with the use of the 
bacterial immunoadjuvant, C. parvum. We found 
that inoculations of tumor cells admixed with C. 
parvum induced the sensitization of preeffector 
cells in the draining lymph nodes (LN) of mice sev- 
eral days later. The subsequent culture of these 
"primed" LN cells led to the generation of potent 
effector cells, as assessed in adoptive immunother- 
apy experiments (51,52). Further studies confirmed 
that the phenotype of in vitro sensitized effector 
lymphocytes was predominantly CD8 + and that 
CD4 ÷ cells were required only as a source of IL-2 
during in vitro differentiation. This fact was verified 
by in vivo depletion techniques of specific T-cell 
subpopulations before TDLN harvest, where CD4 + 
function could be replaced by IL-2 in the IVS cul- 
ture. In adoptive immunotherapy experiments, we 
found that only CD8 ÷ cells were necessary to me- 
diate the regression of pulmonary metastases and 
that the exogenous administration of IL-2 enhanced 
this effect. 
FIG. 3. Survival benefit of adoptive immunother- 
apy of 10-day established pulmonary MCA 105 me- 
tastases with in vitro sensitized lymph node cells 
generated from mice bearing 14-day intrafootpad tu- 
mors (TB-IVS). IVS lymph node cells from normal 
mice (N-IVS) served as control. Each mouse re- 
ceived 3.0 × 107 cells i.v. and exogenous IL-2 i.p. 
(7,500 U/0.5 ml Hanks'  balanced salt solution, twice 
a day for 5 days) (50). 
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The IVS technique has been applied to humans 
with advanced malignancy (53). An autologous tu- 
mor vaccine comprising irradiated tumor cells ad- 
mixed with the bacterial adjuvant BCG was used to 
develop vaccine-primed LN cells for subsequent 
IVS culture. After differentiation and expansion by 
the IVS method, effector cells were transferred to 
patients with concomitant administration of IL-2. 
We found that the majority of patients who received 
in vitro sensitized cells developed cellular reactivity 
to autologous tumor, as assessed by delayed-type 
hypersensitivity reactivity, compared with a cohort 
of patients who were treated by tumor vaccination 
and IL-2 administration only. Despite the transfer 
of cutaneous antitumor reactivity with IVS cells, 
there was limited metastatic tumor regression. This 
finding may be related to insufficient numbers of 
transferred in vitro sensitized cells (median 7 x 109 
per patient), which was due in part to the limited 
quantity of autologous tumor stimulator cells avail- 
able for IVS culture. To help overcome the need for 
tumor during the in vitro activation procedure, al- 
ternative strategies to activate preeffector cells 
have been developed by our laboratory. 
Anti-CD3/IL-2 activated lymphocytes 
A prerequisite to specifically activate sensitized 
T cells in culture requires the binding of antigen to 
the T-cell receptor/CD3 complex expressed on the 
cell surface. Hence, we needed to identify an alter- 
native method to actively sensitize T cells in the 
absence of antigen. A monoclonal antibody to the 
T-cell receptor/CD3 complex (anti-CD3) has been 
found to cause T-cell proliferation and cytokine 
production in a fashion similar to that seen with 
T-cell-receptor binding to antigen (54). From these 
observations, we examined the activation of murine 
TDLN cells with anti-CD3 instead of tumor cells, 
followed by ctdture of these cells in low concentra- 
tions of IL-2. This activation procedure resulted in 
a five- to 10-fold expansion of TDLN cells. The 
adoptive transfer of these anti-CD3/IL-2 activated 
cells mediated the regression of established pulmo- 
nary metastases in murine models (55,56). Although 
T-cell activation by the anti-CD3 antibody was 
potyclonal, the therapeutic effects mediated by 
these cells was immunologically specific, with the 
specificity determined by the tumor that stimulated 
the draining lymph node. 
We have characterized the requirements for op- 
timal anti-CD3/IL-2 culture conditions in animal 
models (Table 3). The activation sequence, amount 
of monoclonal antibody, and IL-2 concentrations 
were all of critical importance for the development 
of therapeutically active effector cells. The effector 
cells generated by the IVS and anti-CD3 activation 
methods were similar in their therapeutic effect on 
a per cell basis. However, they differed in other 
aspects and probably represent either different 
effector cell populations or different stages of dif- 
ferentiation of the same effector cell. The in vitro 
sensitized cells were distinctly different morpholog- 
ically. They were larger and very granular com- 
pared with the anti-CD3/IL-2 activated cells. More- 
TABLE 3. Optimal conditions o f  anti-CD3/IL-2 tumor-draining lymph node cell generation 
Experiment 1 Experiment 2 
Anti-CD3 Mean no. IL-2 Mean no. 
concentration pulmonary concentration pulmonary 
(Ixg/ml)" Expansion b metastases (SEM) c (U/ml) d Expansion b metastases (SEM) c 
- -  - -  243 (7) - -  - -  227 (13) 
100 x7.3 226 (16) 1,000 x I2.3 140 (33) 
10 x6.3 232 (15) 100 ×8.8 184 (26) 
1 x5.8 22 (7) 10 x5.5 1 (1) 
0.1 x2.7 155 (27) 2 x 1.7 3 (2) 
0.01 x t .2  218 (19) 0 x0.6 231 (18) 
0 x0.7 >250 
Modified from Yoshizawa et al. (56). 
TDLN cells bearing 13-day MCA 106 tumors were activated by indicated concentrations of anti-CD3 monoclonal antibody for 2 
days, followed by expansion in 10 U/ml IL-2 for 3 days. 
b Overall expansion after 5 days of culture. 
c B6 mice were injected i.v. with 106 MCA 106 tumor cells to initiate pulmonary metastases. On day 3, activated LN ceils (6-12 x 106) 
were given i.v. to each mouse. IL-2 (15,000 U) was given i.p. twice a day for 4 days. Lungs were harvested, and metastases were counted 
21-24 days after tumor inoculation. 
a TDLN cells bearing 13 day MCA 106 tumors were activated with 1 p~g/mI anti-CD3 monocfonal antibody for 2 days followed by 
expansion in the indicated concentrations of IL-2 for 3 days. 
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over, the CD4/CD8 cell ratio generated by each 
technique was different. Cells cultured by IVS were 
>80% CD8 + cells, whereas anti-CD3/IL-2 acti- 
vated cells were only 60% CD8 ÷. The CD4 ÷ cells 
were required for maturation of the CD8 ÷ cells dur- 
ing anti-CD3 activation, while CD4 ÷ cells in in vitro 
sensitized activation could be replaced by IL-2 (57). 
After activation by either method, it was the CD8 ÷ 
T-cell subpopulation that mediated regression of 
pulmonary metastases after adoptive transfer, with 
exogenous IL-2 helping to maintain their survival 
and function after transfer. 
This anti-CD3/IL-2 activation process generated 
effector cells that were effective in the treatment of 
experimentally induced macrometastatic disease 
confined to one organ site. In a disseminated me- 
tastasis model of B 16/BL6 melanoma (Fig. 4), adop- 
tive immunotherapy with anti-CD3/IL-2 activated 
cells prolonged survival. The poorly immunogenic 
B 16/BL6 murine melanoma is a highly invasive tu- 
mor that has the propensity to spontaneously me- 
tastasize. Animals inoculated with localized tumor 
in the footpad die several weeks later of spontane- 
ous visceral metastases in multiple organs after am- 
putation of the primary tumor inoculum. We have 
documented that adoptive immunotherapy of BI6/ 
BL6 tumor-bearing mice with anti-CD3/IL-2 acti- 
vated cells plus IL-2 significantly prolonged sur- 
vival and cured mice with spontaneous metastases 
(58,59). 
In addition, anti-CD3/iL-2 activated cells can be 
used to eradicate intracranial tumors despite the 
100 
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FIG. 4. Therapeutic efficacy of anti-CD3/IL-2 activated cells 
plus IL-2 in the therapy of spontaneous B 16-BL6 melanoma me- 
tastases. Mice were inoculated with 106 tumor in the footpad and 
underwent amputation of the primary tumor - 3  weeks later, 
when spontaneous visceral metastases were established. Seven 
days after amputation, groups of mice were given no treatment, 
IL-2 only (15,000 U i.p. twice daily × 7 days), or 108 anti-CD3/ 
IL-2 activated cells plus tL-2 (58). 
fact that the brain is a potentially immunoprivileged 
site. In experimental studies we performed, animals 
were transcranially inoculated with 105 MCA 205 
tumor cells. Without treatment, mice succumbed 
within 2-3 weeks; however, after systemic adoptive 
transfer of anti-CD3/IL-2 activated cells, the major- 
ity of mice were permanently cured and resisted 
subsequent intracranial or intravenous tumor chal- 
lenges (J. Sussman, unpublished observations). As 
with the treatment of pulmonary metastases, this 
effect was dose related and immunologically spe- 
cific. However, in contrast to their effect in the 
treatment of pulmonary metastases, the adoptively 
transferred cells were less effective in the presence 
of exogenously administered IL-2. We are now con- 
ducting human trials to evaluate the efficacy of anti- 
CD3/IL-2 activated vaccine-primed lymph node 
cells in the therapy of metastatic melanoma and re- 
nal cell carcinoma. 
The use of anti-CD3 monoclonal antibodies is 
only one method to activate T cells in vitro that 
obviates the need for large amounts of autologous 
tumor for stimulation. Tuttle et al. have used the 
protein kinase activator bryostatin 1 and a calcium 
channel ionophore, ionomycin, to activate TDLN 
cells. They were able to show specific antitumor 
effects mediated by these activated cells (60). More 
recently, in our laboratory, we have exploited the 
T-cell activating properties of the bacterial entero- 
toxins known as superantigens. These compounds 
activate large proportions of T cells based on their 
usage of particular T cell receptor variable chains. 
Using three toxins (SEA, SEB, and SPE A) to stim- 
ulate preeffector cells from MCA 205 TDLNs in 
vitro, we have found that T cells bearing V[~8 may 
preferentially respond to progressively growing tu- 
mors than T cells expressing V[33 and V[311 (61). 
These observations may allow us to pinpoint more 
selective strategies to stimulate tumor-immune T 
cells for the generation of effector cells. 
Hampering the development of effective immu- 
notherapy of human cancer is the poorly defined 
immunosuppression that occurs in cancer patients. 
North and co-workers verified the presence of tu- 
mor suppressor cells in tumor-bearing hosts that ab- 
rogated the antitumor reactivity of adoptively trans- 
ferred immune lymphocytes (23). This suppression 
was eliminated by treating the tumor-bearing host 
with whole-body irradiation or administering cyclo- 
phosphamide before transfer of immune cells. 
There is significantly less information regarding the 
phenomenon of tumor-induced suppression that 
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TABLE 4. Immunological ly  specific' suppression o f  the 
host  immune  response to subcutaneous tumor 
Adoptive immunotherapy b 
Source of TDLNs a 
Mean no. 
Subcutaneous Visceral Cells pulmonary 
tumor tumor transferred metastases (SEM) 
- -  - -  - -  >250 
MCA 106 None + 1 (<1) 
MCA 106 MCA 106 + 240 (10) 
MCA 106 MCA 205 + 1 (<1) 
For the generation of effector cells, mice were inoculated 
s.c. in the flank with MCA 106 tumor. Some mice were also 
inoculated the same clay i.v. with the indicated tumor to establish 
a visceral tumor burden. Twelve days later, the subcutaneous 
tumor-draining LNs were activated by the anti-CD3/IL-2 
method. 
b Mice with established 4-day MCA 106 pulmonary metastases 
were given 2 x 107 anti-CD3/IL-2 activated cells. All mice re- 
ceived IL-2 (15,000 U twice daily) for 4 days after transfer of 
cells. 
may inhibit the development of immune cells. Until 
recently, experimental models of adoptive immuno- 
therapy (i.e., TILs, IVS, or anti-CD3/IL-2 stimu- 
lated lymph nodes) have used lymphoid cells de- 
rived from donor animals bearing localized subcu- 
taneous tumors in the absence of visceral tumors. 
We have found that the presence of visceral tumor 
can suppress the development of sensitized lym- 
phocytes obtained from lymph nodes draining sub- 
cutaneous tumors in the same host (Table 4) (V. 
Sondak, unpublished observations). Thus, the abil- 
ity to isolate antitumor effector cells from the tu- 
mor-bearing host remains an important area of ex- 
perimental investigation. 
CONCLUSION 
Advances in the immunologic treatment of tu- 
mors have paralleled our understanding of the 
mechanisms that play a part in T-cell antigen rec- 
ognition. As we learn more about T-cell-receptor 
structure, signal transduction pathways, and the 
structure of antigens, alternate methods to activate 
T cells reactive to tumor antigens should become 
apparent. Advances in molecular genetic tech- 
niques may be used in the future to modulate the 
immune system in favor of mediating regression of 
established malignancies. Our laboratory as well as 
others have shown that the immunobiology of tu- 
mors can be altered by genetically modifying tumor 
cells to express allogeneic MHC class I antigens 
(11); costimulatory molecules, such as the B7 tigand 
(12,13); or suppressive growth factors, such as 
IGF-I (62). They may also be genetically engineered 
to secrete cytokines (6-10). The significance of 
these findings in the development of clinical immu- 
notherapeutic approaches remains to be estab- 
lished. It is also possible that genes may be directly 
targeted into antitumor T cells, either by in vivo or 
in vitro techniques, to enhance their survival or 
therapeutic activity. To date, it is clear that T-cell 
therapy of human cancer is feasible and therapeu- 
tically effective in selected patients. Methods to im- 
prove our ability to develop tumor-specific immune 
T cells will greatly improve the application of this 
approach to a broader range of patients. 
Acknowledgment: Research  was supported in part by 
Amer ican  Cancer  Socie ty  grants: a pos tdoctora l  research  
fellowship (J. J. S.), a career  deve lopment  award (V.K.S. ) ,  
and a faculty research award (A.E.C.) .  The  authors  thank 
Ms. Debbie Birdsall for  her  excel lent  assis tance in the 
preparat ion of the text.  
REFERENCES 
1. Hersh EM, Taylor CW. Immunotherapy by active immuni- 
zation: use of nonspecific stimulants and immunomoduta- 
tors. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Phil- 
adelphia: JB Lippincott, 1991;613-26. 
2. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, 
Rosenberg SA. High-dose recombinant interleukin-2 in the 
treatment of patients with disseminated cancer. JAMA 1986; 
256:3117-24. 
3. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with 
the use of high-dose interleukin-2 in the treatment of 652 
cancer patients. Ann Surg 1989;210:474-85. 
4. Sosman JA, Kohler PC, Hank J, et al. Repetitive weekly 
cycles of recombinant human interleukin-2: responses of re- 
nal carcinoma with acceptable toxicity. JNCI 1988;80:60-3. 
5. Parkinson DR, Abrams JS, Wiernik PH, et al. Interleukin-2 
therapy in patients with metastatic malignant melanoma: a 
Phase II study. J Clin Oncol 1990;8:1650-6. 
6. Tepper RI, Coffman RL, Leder P. An eosinophil-dependant 
mechanism for the antitumor effect of interleukin-2. Science 
1992 ;257:548-51. 
7. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, 
Gilboa E. Interleukin-2 gene transfer into tumor cells abro- 
gates tumorigenicity and induces protective immunity. J Exp 
Med 1990;172:1217-24. 
8. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, 
Gilboa E. Retroviral vector-mediated "y-interferon gene 
transfer into tumor cells generates potent and long lasting 
antitumor immunity. Cancer Res 1990;50:7820-5. 
9. Asher AL, Mule J J, Kasid A, et al. Evidence for paracrine 
immune effects of tumor necrosis factor against tumors. J 
Immunol 1991;146:3227-34. 
10. Restifo NP, Spiess PJ, Karp SE, Mule JJ, Rosenberg SA. A 
nonimmunogenic sarcoma transduced with the eDNA for 
interferon,/elicits CD8 + T cells against the wild-type tumor: 
correlation with antigen presentation capability. J Exp Med 
1992;175:1423-31. 
11. Wahl WL, Plautz GP, Fox BA, Nabel G J, Shu S, Chang AE. 
Generation of therapeutic T lymphocytes after in vivo trans- 
fection of tumor with a gene encoding allogeneic class I 
MHC antigen. Surg Forum 1992;43:476-8. 
12~ Chert L, Ashe S, Brady WA, et al. Costimulation of antitu- 
mor immunity by the B7 counterreceptor for the T lympho- 
Ann Surg Oncol, Vol. 1, No. 4, 1994 
A D O P T I V E  I M M U N O T I t E R A P Y  O F  C A N C E R  305  
cyte molecules CD28 and CTLA-4. Cell 1992;71:1093-102. 
13. Townsend SE, Allison JP. Tumor rejection after direct co- 
stimulation of CD8 + T cells by B7-transfected melanoma 
cells. Science 1993;259:368-70. 
14. Rosenberg SA, Terry WD. Passive immunotherapy of can- 
cer in animals and man. Adv Cancer Res 1977;25:323. 
15. Scheinberg DA, Strand M. Radioimmunotherapy in experi- 
mental animal models: principles derived from models. Can- 
cer Res 1990;50:962s-3s. 
16. Order SE, Sleeper AM, StiUwagon GB, Klein JL, Leichner 
PK. Radiolabeled antibodies: results and potential in cancer 
therapy. Cancer Res 1990;50:1011s-13s. 
17. Sela M, Hurwitz E. Conjugates of antibodies with cytotoxic 
drugs. In: Vogel CW, ed. Immunoconjugates. New York: 
Oxford University Press, 1987;189-216. 
18. Pastan I, Fitzgerald D. Recombinant toxins for cancer treat- 
ment. Science 1991 ;254:1173-7. 
19. Urban JL, Schreiber H. Tumor antigens. Annu Rev Immunol 
1992;10:617-44. 
20. Abe M, Kufe DW. Identification of a family of high molec- 
ular weight tumor-associated glycoproteins. J Immunol  
1987;139:257-61. 
21. Cheever MA, Greenberg PD, Fefer A. Potential for specific 
cancer therapy with immune T lymphocytes. J Biol Resp 
Mod 1984;3: t 13-27. 
22. Greenberg PD. Adoptive T cell therapy of tumors: mecha- 
nisms operative in the recognition and elimination of tumor 
cells. Adv Immunol 1991 ;49:281-355. 
23. North RJ. The murine antitumor immune response and its 
therapeutic manipulation. Adv Immunol 1984;35:89-155. 
24. Chang AE, Shu S, Chou T, Lafreniere R, Rosenberg SA. 
Differences in the effects of host suppression on the adop- 
tive immunotherapy of subcutaneous and visceral tumors. 
Cancer Res 1986;46:3426-30. 
25. Sondak VK, Wagner PD, Shu S, Chang AE. Suppressive 
effects of visceral tumor on the generation of antitumor T 
cells for adoptive immunotherapy. Arch Surg 1991;126: 
442-6. 
26. Grimm EA, Robb RJ, Roth JA, et al. Lymphokine-activated 
killer cell phenomenon III. Evidence that IL-2 is sufficient 
for direct activation of peripheral blood lymphocytes into 
lymphokine-acfivated killer cells. J Exp Med 1983;158:1356-- 
61. 
27. Mule JJ, Shu S, Schwarz SL, et al. Adoptive immunother- 
apy of established pulmonary metastases with LAK cells 
and recombinant interleukin-2. Science 1984;225:1487-9. 
28. Mule JJ, Shu S, Rosenberg SA. The anti-tumor efficacy of 
lymphokine-activated killer cells and recombinant interleu- 
kin-2 in vivo. J Immunol 1985;135:646-52. 
29. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on 
the systemic administration of autologous lymphokine- 
activated killer cells and recombinant interleukin-2 to pa- 
tients with metastatic cancer. N Engl J Med 1985;313:1485- 
92. 
30. Rosenberg SA. The development of new immunotherapies 
for the treatment of cancer using interleukin-2. Ann Surg 
1988;208:121-35. 
31. West WH, Tauer KW, Yannelli JR, et al. Constant-infusion 
recombinant interleukin-2 in adoptive immunotherapy of ad- 
vanced cancer. N Engl J Med 1987;316:898--905. 
32. Schoof DD, Gramolini BA, Davidson DL, Massaro AF, Wil- 
son RE, Eberlein TJ. Adoptive immunotherapy of human 
cancer using low-dose recombinant interleukin-2 and lym- 
phokine-activated killer cells. Cancer Res 1988;48:5007-10. 
33. Thompson JA, Lee DJ, Lindgren CG, et al. Influence of 
schedule of interleukin-2 administration on therapy with in- 
terleukin-2 and lymphokine activated killer cells. Cancer 
Res 1989;49:235-40. 
34. Paciucci PA, Holland JF, Glidewell O, Odchimar R. Recom- 
binant interleukin-2 by continuous infusion and adoptive 
transfer of recombinant intefleukin-2 activated cells in pa- 
tients with advanced cancer. J Clin Oncol 1989;7:869-78. 
35. Dutcher JP, Creekmore S, Weiss GR, et al. A Phase II study 
of interleukin-2 and lymphokine-activated killer cells in pa- 
tients with metastatic malignant melanoma. J Clin Oncol 
1989;7:477-85. 
36. Bar MH, Sznol M, Atkins MB, et al. Metastatic malignant 
melanoma treated with combined bolus and continuous in- 
fusion interleukin-2 and lymphokine activated killer cells. J 
Clin Oncol 1990;8:1138-47. 
37. Dutcher JP, Gaynor ER, Boldt DH, et al. A Phase II study 
of high-dose continuous fusion interleukin-2 with lympho- 
kine-activated killer cells in patients with metastatic mela- 
noma. J Clin Oncol 1991;9:641-8. 
38. Wang JCL, Walle A, Novogrodsky A, et al. A Phase II 
clinical trial of adoptive immunotherapy for advanced renal 
cell carcinoma using mitogen-activated autologous leuko- 
cytes and continuous infusion interleukin-2. J Clin Oncol 
1989;7:1885-91. 
39. Fisher RI, Coltman CA, Doroshow JH, et al. Metastatic 
renal cell cancer treated with interleukin-2 and lymphokine- 
activated killer cells: a Phase II clinical trial. Ann Intern Med 
1988;108:518-23. 
40. Parkinson DR, Fisher RI, Rayner AA, et al. Therapy of renat 
cell carcinoma with interleukin-2 and lymphokine-activated 
killer cells: Phase II experience with a hybrid bolus and 
continuous infusion interleukin-2 regimen. J Clin Oncol 
1990;8:163ff45. 
41. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991; 
9:694-704. 
42. McCabe M, Stablein D, Hawkins MJ. The modified group C 
experience: Phase III randomized trails of IL-2 vs. IL-2/ 
LAK in advanced renal cell cancer and advanced melanoma 
(Abst. 714). Proceedings o f  the American Society o f  Clinical 
Oncology 1991;10:213. 
43. Rosenberg SA, Yang JC, Topalian SL, et al. Prospective 
randomized trial of high dose interleukin-2 alone or with 
lymphokine activated killer cells for the treatment of pa- 
tients with advanced cancer. JNCI  !993;85:622-32. 
44. Rosenberg SA, Spiess P, Lafreniere R. A new approach to 
the adoptive immunotherapy of cancer with tumor- 
infiltrating lymphocytes. Science 1986;233:1318-21. 
45. Spiess PJ, Yang JC, Rosenberg SA. In vivo antitumor activ- 
ity of tumor-infiltrating lymphocytes expanded in recombi- 
nant interleukin-2. JNCI  1987;79:1067-75. 
46. Aebersold P, Hyatt C, Johnson S, et al. Lysis of autologous 
melanoma cells by tumor-infiltrating lymphocytes: associa- 
tion with clinical response. JNCI  1991 ;83:932-7. 
47. Bukowski RM, Sharfman W, Murthy S, et at. Clinical results 
and characterization of tumor-infiltrating lymphocytes with 
or without recombinant interleukin-2 in human metastatic 
renal cell carcinoma. Cancer Res 1991;51:4199-205. 
48. Shu S, Chou T, Rosenberg SA. Generation from tumor- 
bearing mice of lymphocytes with in vitro therapeutic effi- 
cacy. J lmmunol 1987;139:295-304. 
49. Chou T, Chang AE, Shu S. Generation of therapeutic T 
lymphocytes from tumor-bearing mice by in vitro sensitiza- 
tion: culture requirements and characterization of immuno- 
logic specificity. J Immunol 1988;140:2453-61. 
50. Chou T, Bertera S, Chang AE, Shu S. Adoptive immuno- 
therapy of microscopic and advanced visceral metastases 
with in vitro sensitized lymphoid cells from mice bearing 
progressive tumors. J Immunol 1988;141:1775-81. 
51. Shu S, Chou T, Sakai K. Lymphocytes generated by in vivo 
priming and in vitro sensitization demonstrate therapeutic 
efficacy against a murine tumor that lacks apparent immu- 
nogenicity. J Immunol 1989;143:740-8. 
52. Sakai K, Chang AE, Shu S. Effector phenotype and immu- 
Ann Surg Oncol, Vol. I, No. 4, 1994 
306  J .  J .  S U S S M A N  E T  A L .  
nologic specificity of T cell-mediated adoptive therapy for a 
murine tumor that lacks intrinsic immunogenicity. Cell Im- 
munol 1990;129:241-55. 
53. Chang AE, Yoshizawa H, Sakai K, Cameron M J, Sondak 
VK, Shu S. Clinical observations on adoptive immunother- 
apy with vaccine-primed T lymphocytes secondarily sensi- 
tized to tumor in vitro. Cancer Res 1993;53:1043-50. 
54. Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA. 
Proc Natl  Acad Sci USA 1987;84:1374. 
55. Yoshizawa H, Sakai K, Chang AE, Shu S. Activation by 
anti-CD3 of tumor-draining lymph node cells for specific 
adoptive immunotherapy. Cell lmmunol 1991 ;134:473-9. 
56. Yoshizawa H, Chang AE, Shu S. Specific adoptive immu- 
notherapy mediated by tumor-draining lymph node cells se- 
quentially activated with anti-CD3 and IL-2. J Immunol 
1991 ;147:72%37. 
57. Yoshizawa H, Chang AE, Shu S. Cellular interactions in 
effector cell generation and tumor regression mediated by 
anti-CD3/interleukin-2 activated tumor-draining lymph node 
cells. Cancer Res 1992;52:1129-36. 
58. Geiger JD, Wagner PD, Cameron MJ, Shu S, Chang AE. 
Generation of T cells reactive to the poorly immunogenic 
Bt6-BL6 melanoma with efficacy in the treatment of spon- 
taneous metastases. J lmmunother 1993; 13:153-65. 
59. Geiger JD, Wagner PD, Shu S, Change AE. A novel role for 
autologous tumor cell vaccination in the immunotherapy of 
the poorly immunogenic B16-BL6 melanoma. Surg Oncol 
1992;t:199-208. 
60. Tuttle TM, Inge TH, Bethke KP, McCrady CW, Pettit GR, 
Bear HD. Activation and growth of murine tumor-specific T 
cells which have in vivo activity with bryostatin 1. Cancer 
Res 1992;52(3):548-53. 
61. Shu S, Krinock RA, Matsumura T, et al. Stimulation of tu- 
mor-draining lymph node cells with superantigenic staphy- 
lococcal toxins leads to the generation of tumor-specific ef- 
fector T cells, J Immunol (in press). 
62. Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML, 
Ilan J. Treatment and prevention of rat glioblastoma by im- 
munogenic C6 cells expressing antisense insulin-like growth 
factor I RNA. Science 1993;259:94-7. 
Ann Surg Oncol, Vol. 1, No. 4, 1994 
